DE69636122D1 - Verfahren zur einführung von genen in zielzellen mit hilfe von retroviren - Google Patents

Verfahren zur einführung von genen in zielzellen mit hilfe von retroviren

Info

Publication number
DE69636122D1
DE69636122D1 DE69636122T DE69636122T DE69636122D1 DE 69636122 D1 DE69636122 D1 DE 69636122D1 DE 69636122 T DE69636122 T DE 69636122T DE 69636122 T DE69636122 T DE 69636122T DE 69636122 D1 DE69636122 D1 DE 69636122D1
Authority
DE
Germany
Prior art keywords
retrovirus
target cells
help
effective amount
functional material
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69636122T
Other languages
English (en)
Other versions
DE69636122T2 (de
Inventor
Kiyozo Asada
Takashi Uemori
Takashi Ueno
Nobuto Koyama
Kimikazu Hashino
Ikunoshiu Kato
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takara Bio Inc
Original Assignee
Takara Bio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takara Bio Inc filed Critical Takara Bio Inc
Application granted granted Critical
Publication of DE69636122D1 publication Critical patent/DE69636122D1/de
Publication of DE69636122T2 publication Critical patent/DE69636122T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/505—Erythropoietin [EPO]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1085—Transferases (2.) transferring alkyl or aryl groups other than methyl groups (2.5)
    • C12N9/1088—Glutathione transferase (2.5.1.18)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/13043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/13045—Special targeting system for viral vectors
DE69636122T 1995-11-13 1996-11-07 Verfahren zum gentransfer in zielzellen mit einem retrovirus Expired - Lifetime DE69636122T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP29438295 1995-11-13
JP29438295 1995-11-13
JP5184796 1996-03-08
JP5184796 1996-03-08
PCT/JP1996/003254 WO1997018318A1 (en) 1995-11-13 1996-11-07 Method for gene introduction into target cells by retrovirus

Publications (2)

Publication Number Publication Date
DE69636122D1 true DE69636122D1 (de) 2006-06-14
DE69636122T2 DE69636122T2 (de) 2006-12-07

Family

ID=26392431

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69636122T Expired - Lifetime DE69636122T2 (de) 1995-11-13 1996-11-07 Verfahren zum gentransfer in zielzellen mit einem retrovirus

Country Status (13)

Country Link
US (5) US6472204B1 (de)
EP (1) EP0870839B1 (de)
JP (1) JP3343357B2 (de)
KR (2) KR100395420B1 (de)
CN (1) CN100390290C (de)
AT (1) ATE325884T1 (de)
AU (1) AU709831B2 (de)
CA (1) CA2235629A1 (de)
DE (1) DE69636122T2 (de)
EA (3) EA004928B1 (de)
ES (1) ES2259182T3 (de)
MX (1) MX9803706A (de)
WO (1) WO1997018318A1 (de)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7083979B1 (en) 1994-03-25 2006-08-01 Indiana University Foundation Methods for enhanced retroviral-mediated gene transfer
DK1445322T4 (da) 1995-06-15 2012-09-03 Crucell Holland Bv Pakningssystemer for humant rekombinant adenovirus til anvendelse ved genterapi
CA2233316C (en) * 1995-09-29 2010-12-14 Indiana University Foundation Methods for enhanced virus-mediated dna transfer using molecules with virus- and cell-binding domains
TWI239352B (en) * 1997-07-23 2005-09-11 Takara Bio Inc Gene transfer method with the use of serum-free medium
JP2001523468A (ja) * 1997-11-14 2001-11-27 セダーシナイ メディカル センター トランスジェニック種の産生のための雄性生殖細胞のトランスフェクションおよび移入
JP3807937B2 (ja) * 1998-07-01 2006-08-09 タカラバイオ株式会社 遺伝子導入方法
US7198909B1 (en) * 1998-10-31 2007-04-03 University Of Medicine & Dentistry Of New Jersey Myeloid precursor cell useful for gene therapy and for modulation of immune responses
AU2944100A (en) * 1999-03-23 2000-10-09 Takara Shuzo Co., Ltd. Gene therapeutics
US7309687B1 (en) 1999-04-13 2007-12-18 The Kenneth S. Warren Institute, Inc. Methods for treatment and prevention of neuromuscular and muscular conditions by peripherally administered erythropoietin
US7345019B1 (en) 1999-04-13 2008-03-18 The Kenneth S. Warren Institute, Inc. Modulation of excitable tissue function by peripherally administered erythropoietin
US7604960B2 (en) * 1999-04-15 2009-10-20 Crucell Holland B.V. Transient protein expression methods
US7297680B2 (en) 1999-04-15 2007-11-20 Crucell Holland B.V. Compositions of erythropoietin isoforms comprising Lewis-X structures and high sialic acid content
US20050170463A1 (en) * 1999-04-15 2005-08-04 Abraham Bout Recombinant protein production in permanent amniocytic cells that comprise nucleic acid encoding adenovirus E1A and E1B proteins
US20050164386A1 (en) * 1999-04-15 2005-07-28 Uytdehaag Alphonsus G. Overexpression of enzymes involved in post-translational protein modifications in human cells
US6855544B1 (en) * 1999-04-15 2005-02-15 Crucell Holland B.V. Recombinant protein production in a human cell
US8236561B2 (en) * 1999-04-15 2012-08-07 Crucell Holland B.V. Efficient production of IgA in recombinant mammalian cells
GB9912965D0 (en) * 1999-06-03 1999-08-04 Oxford Biomedica Ltd In vivo selection method
AU5958000A (en) * 1999-07-08 2001-01-30 Connie Jean Eaves Method to improve viral infection
US7192759B1 (en) 1999-11-26 2007-03-20 Crucell Holland B.V. Production of vaccines
US7527961B2 (en) * 1999-11-26 2009-05-05 Crucell Holland B.V. Production of vaccines
US7521220B2 (en) * 1999-11-26 2009-04-21 Crucell Holland B.V. Production of vaccines
AU2001285263A1 (en) 2000-08-25 2002-03-13 The General Hospital Corporation Selective precipitation of viruses
PA8536201A1 (es) 2000-12-29 2002-08-29 Kenneth S Warren Inst Inc Protección y mejoramiento de células, tejidos y órganos que responden a la eritropoyetina
US6531121B2 (en) 2000-12-29 2003-03-11 The Kenneth S. Warren Institute, Inc. Protection and enhancement of erythropoietin-responsive cells, tissues and organs
US8742091B2 (en) * 2001-06-20 2014-06-03 Dainippon Sumitomo Pharma Co., Ltd. Method of promoting nucleic acid transfer
JP2005052001A (ja) * 2001-07-05 2005-03-03 Takara Bio Inc 遺伝子治療剤
KR100888915B1 (ko) 2001-08-15 2009-03-16 다카라 바이오 가부시키가이샤 항원특이적 세포상해성 ｔ 세포 확대배양방법
KR100979025B1 (ko) * 2001-12-07 2010-08-30 크루셀 홀란드 비.브이. 바이러스, 바이러스 단리물 및 백신의 생산
CN100591760C (zh) 2002-03-25 2010-02-24 宝生物工程株式会社 制备细胞毒性淋巴细胞的方法
US20100143442A1 (en) 2003-02-05 2010-06-10 Queensland University Of Technology Growth factor complexes and modulation of cell migration and growth
US20040219099A1 (en) * 2003-05-02 2004-11-04 Jasbir Sandhu Method for the treatment of tumors
US20040220085A1 (en) * 2003-05-02 2004-11-04 Jasbir Sandhu Compositions for nucleic acid delivery
ATE414144T1 (de) 2003-05-09 2008-11-15 Crucell Holland Bv Kulturen von e1-immortalisierten zellen und verfahren zu deren kultivierung zur erhöhung der produktausbeuten davon
DK1626992T3 (da) * 2003-05-23 2010-09-20 Crucell Holland Bv Produktion af rekombinant IgM i PER.C6-celler
FR2857598A1 (fr) * 2003-07-18 2005-01-21 Inst Nat Sante Rech Med Composes anti-angiogeniques, composition pharmaceutique les comprenant, et leur utilisation
MXPA06002039A (es) 2003-08-22 2006-05-25 Takara Bio Inc Proceso para producir linfocitos citotoxicos.
GB0410130D0 (en) * 2004-05-06 2004-06-09 Molmed Spa Cell preparation
US9057056B2 (en) * 2004-09-29 2015-06-16 Takara Bio Inc. Method for producing retrovirus using human producer cells with increased N-acetylglucosaminyltransferase III activity
CN101115830B (zh) * 2005-02-07 2012-09-05 宝生物工程株式会社 逆转录病毒储存方法
EP1892294A4 (de) 2005-06-15 2010-04-14 Takara Bio Inc Verfahren zum transfer von genen in fettzellen oder vorläuferfettzellen
CA2616863A1 (en) * 2005-07-29 2007-02-01 Australian Stem Cell Centre Limited Compositions and methods for growth of pluripotent cells
US8889844B2 (en) 2005-08-16 2014-11-18 Takara Bio Inc. Nucleic acid for treatment or prevention of immunodeficiency virus infection
EP1916302A4 (de) 2005-08-17 2009-10-21 Takara Bio Inc Verfahren zur herstellung von lymphozyten
JP4741906B2 (ja) * 2005-08-31 2011-08-10 タカラバイオ株式会社 リンパ球の製造方法
CA2623735A1 (en) * 2005-09-30 2007-04-12 Takara Bio Inc. Method for production of t cell population
KR20090024782A (ko) * 2006-06-09 2009-03-09 다카라 바이오 가부시키가이샤 림프구의 제조 방법
EP2138580B1 (de) 2007-04-20 2013-03-20 Takara Bio, Inc. Vektor für gentherapie
EP2267118A4 (de) 2008-03-27 2013-08-28 Takara Bio Inc Verfahren zur herstellung einer transfizierten zelle
CN102144027B (zh) * 2008-07-07 2016-04-06 宝生物工程株式会社 生产多能干细胞的方法
WO2010080032A2 (en) * 2009-01-09 2010-07-15 Stichting Het Nederlands Kanker Instituut Bead-assisted viral transduction
WO2011024791A1 (ja) 2009-08-25 2011-03-03 タカラバイオ株式会社 レチノイン酸存在下でのｔ細胞集団の製造方法
JP5792622B2 (ja) 2009-09-11 2015-10-14 タカラバイオ株式会社 ナチュラルキラー細胞の製造方法
CN102725308A (zh) * 2009-11-30 2012-10-10 昆士兰技术大学 纤连蛋白:生长因子嵌合物
US9228206B2 (en) 2010-06-30 2016-01-05 Takara Bio Inc. Method for gene transfer
JP5778147B2 (ja) * 2010-06-30 2015-09-16 タカラバイオ株式会社 遺伝子導入方法
US9861681B2 (en) 2013-04-18 2018-01-09 The United States of America as represented by the Secretary of the Army, on behalf of the United States Army Medical Research Institute of Infectious Diseases Therapeutic compositions for neutralizing type I interferons, and methods of use
CN109790536A (zh) 2016-07-29 2019-05-21 宝生物工程株式会社 用于干细胞产生的纤连蛋白片段
US11524988B2 (en) 2016-09-19 2022-12-13 H. Lee Moffitt Cancer Center And Research Institute, Inc. Artificial antigen presenting cells for genetic engineering of immune cells
CN108103045B (zh) * 2016-11-25 2022-10-04 丰益(上海)生物技术研发中心有限公司 脂肪酶及其应用
IL292456B (en) 2017-02-22 2022-08-01 Lumus Ltd Optical assembly of a light guide
US20200181260A1 (en) * 2017-02-22 2020-06-11 H. Lee Moffitt Cancer Center And Research Institute, Inc. Bispecific antibody for cancer immunotherapy
CN111655842B (zh) 2018-01-25 2023-10-20 宝生物工程株式会社 淋巴细胞生产方法
AU2020211092B2 (en) 2019-01-24 2023-05-11 Lumus Ltd. Optical systems including LOE with three stage expansion
CN114901793A (zh) * 2019-12-30 2022-08-12 美国圣戈班性能塑料公司 用于细胞转导的容器和方法
CN113444167B (zh) * 2021-07-15 2022-09-30 陕西巨子生物技术有限公司 重组人胶原蛋白多肽及其应用
CN114634984A (zh) * 2022-02-02 2022-06-17 复旦大学 一种脑胶质瘤生物标记物mlkl基因及其应用
WO2023213969A1 (en) * 2022-05-05 2023-11-09 Juno Therapeutics Gmbh Viral-binding protein and related reagents, articles, and methods of use
CN114965839A (zh) * 2022-05-11 2022-08-30 朗肽生物制药股份有限公司 人碱性成纤维细胞生长因子的肽图分析方法
CN117645664A (zh) * 2024-01-29 2024-03-05 英特菲尔(成都)生物制品有限责任公司 重组人纤连蛋白标准品及其制备方法、鉴定方法与应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8516421D0 (en) * 1985-06-28 1985-07-31 Biotechnology Interface Ltd Fibronectins
US4994559A (en) 1985-12-17 1991-02-19 Synergen, Inc. Human basic fibroblast growth factor
US5026839A (en) 1985-12-17 1991-06-25 Synergen, Inc DNA encoding a basic fibroblast growth factor
JP2770926B2 (ja) * 1985-12-17 1998-07-02 サイナーゲン インコーポレーテッド 毛管内皮細胞プロテアーゼ合成、ｄｎａ合成および遊走を促進することの出来るヒト胎盤血管形成誘導因子
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
US5492890A (en) * 1990-12-03 1996-02-20 The Scripps Research Institute Polypeptides for promoting cell attachment
DE4110409C2 (de) * 1991-03-29 1999-05-27 Boehringer Ingelheim Int Neue Protein-Polykation-Konjugate
JP2829405B2 (ja) * 1991-10-14 1998-11-25 寳酒造株式会社 機能性ポリペプチド
SE503225C2 (sv) * 1991-10-30 1996-04-22 Leif Lindholm Konsult Ab Virus-antikroppskomplex för införing av virus i mammalieceller
CH685803A5 (fr) * 1992-06-09 1995-10-13 Francis Verdan Bâton d'alun fixé dans un étui.
GB9223084D0 (en) * 1992-11-04 1992-12-16 Imp Cancer Res Tech Compounds to target cells
US5686278A (en) 1994-03-25 1997-11-11 Indiana University Foundation Methods for enhanced retrovirus-mediated gene transfer
JPH1029952A (ja) 1996-07-16 1998-02-03 Takara Shuzo Co Ltd ヒト免疫不全ウイルス感染の制御用組成物および制御方法

Also Published As

Publication number Publication date
US6472204B1 (en) 2002-10-29
KR19990067446A (ko) 1999-08-16
CA2235629A1 (en) 1997-05-22
DE69636122T2 (de) 2006-12-07
US20090209730A1 (en) 2009-08-20
ES2259182T3 (es) 2006-09-16
US20060030046A1 (en) 2006-02-09
EA200200837A1 (ru) 2002-12-26
CN100390290C (zh) 2008-05-28
EA199800369A1 (ru) 1998-12-24
US7446170B2 (en) 2008-11-04
CN1207774A (zh) 1999-02-10
AU7505896A (en) 1997-06-05
EA003195B1 (ru) 2003-02-27
EP0870839A4 (de) 2000-01-19
US6949623B2 (en) 2005-09-27
EA004928B1 (ru) 2004-10-28
US7790849B2 (en) 2010-09-07
WO1997018318A1 (en) 1997-05-22
AU709831B2 (en) 1999-09-09
JP3343357B2 (ja) 2002-11-11
US20030087437A1 (en) 2003-05-08
EA200001110A1 (ru) 2001-06-25
EA003204B1 (ru) 2003-02-27
EP0870839B1 (de) 2006-05-10
KR100353115B1 (ko) 2003-01-06
KR100395420B1 (ko) 2003-08-21
US6426042B1 (en) 2002-07-30
EP0870839A1 (de) 1998-10-14
ATE325884T1 (de) 2006-06-15
MX9803706A (es) 1998-09-30

Similar Documents

Publication Publication Date Title
DE69636122D1 (de) Verfahren zur einführung von genen in zielzellen mit hilfe von retroviren
ATE345682T1 (de) In vitro verfahren zum einbringen von nukleinsäuren in eine zelle
AU2161501A (en) Immobilized single domain antigen-binding molecules
DE69706187D1 (de) Zusammensetzungen und verfahren zur immobilisierung von nukleinsäure auf festträgern
ATE414171T1 (de) Verfahren zur immobilisierung von oligonukleotiden auf festem trägermaterial
AU2894289A (en) Domain-modified constant region antibodies
DE3673501D1 (de) Mittel und verfahren zur funktionalisierung von nukleinsaeuren.
DE69637579D1 (de) Methode zur Amplifizierung von Nukleinsäure und entsprechende Regenzien dafür
DE69024447T2 (de) Induzierer einer tumorlysierenden Zelle, Verfahren und Gerät zur Induzierung tumorlysierender Zellen
DE59107591D1 (de) Immobilisierung von organischen makromolekülen oder biopolymeren in einer polymermembran
ATE70916T1 (de) Mit ueberzuegen versehene formkoerper zur bindung von bioaffinen substanzen.
DE69835813D1 (de) Verfahren zur kultivierung von zellen und zur vermehrung von viren
EP1083980A4 (de) Modulation molekularer wechselwirkungspositionen in rns und anderen biomolekülen
DK0868511T3 (da) Genekspression af utrophin
DE69514415T2 (de) Verfahren zur Herstellung von Dioxazinverbindungen,damit gefärbte Materialien und Dioxazinverbindungen mit plattenartiger Kristallform.
ATE389727T1 (de) Modulatoren der expression von morphogenen und deren identifizierungsverfahren
DE59700281D1 (de) Verfahren zur Herstellung von Aminoessigsäuren mit alpha-ständigem tertiären Kohlenwasserstoffrest oder deren Nitrilen
DE69704885D1 (de) Zusammensetzung und Verfahren zur Leimung von flächigen Strukturen
RU2000106030A (ru) Способ воздействия на связывание p53 с геном-мишенью
ATA33696A (de) Verfahren zum immobilisieren von schadstoffen und festkörper mit immobilisierten schadstoffen
AUPO654597A0 (en) Nucleic acid molecules specific for bacterial antigens and uses thereof
ATE55608T1 (de) Mittel und verfahren zur funktionalisierung von nukleinsaeuren.
AUPO816297A0 (en) Nucleic acid molecules specific for bacterial antigens and uses thereof (II)

Legal Events

Date Code Title Description
8364 No opposition during term of opposition